Advertisement

Picture [iito] No Tracking 650x80px
Organisation › Details

Prexton Therapeutics B.V.

Prexton is a biopharmaceutical company founded in 2012 by Francois Conquet and M Ventures, the corporate venture arm of Merck KGaA, their entrepreneurial partnership program, which supports the creation of spin-offs from Merck. Prexton applies a new scientific approach that fully integrates molecular, behavioral and chemistry technologies to address Parkinson's disease and other brain disorders. Prexton is based in Oss (The Netherlands) and in Geneva (Switzerland). Other major investors include Forbion, Seroba Life Sciences, Sunstone Capital and Ysios Capital. About foliglurax Foliglurax (PTX002331) is a small-molecule positive allosteric modulator of group III metabotropic glutamate receptor 4 (mGluR4 PAM), for the potential oral treatment of Parkinson's disease. A single- and multiple-ascending oral dose phase I trial (NCT02639221) in healthy volunteers with foliglurax was successfully completed in 2016. The results showed that foliglurax appears well-tolerated with a satisfactory pharmacokinetic (how the drug is processed in the body) profile. In July 2017, Prexton initiated a phase II clinical trial (NCT03162874) with foliglurax. The trial will enroll around 165 Parkinson's patients in sites across six European countries (U.K., Germany, France, Austria, Spain, and Italy). The double-blinded, randomized, placebo-controlled, parallel-arm study will assess the effectiveness, safety, and tolerability of foliglurax in reducing motor complications of levodopa therapy in patients experiencing end-of-dose wearing-off and levodopa-induced dyskinesia. Two groups will receive oral doses (10 mg and 30 mg) of the treatment over 28 days, in addition to their standard medication, incl. levodopa. A third group will receive placebo. The primary outcome measure will be the change in the daily awake "OFF"-time (i.e. time where the treatment does not work) based on patient diary entries between the start and end of treatment. The study is expected to be completed in 2019. *

 

Period Start 2012-07-30 splitoff
  Group Lundbeck (Group)
  Predecessor Prexton Therapeutics S.A.
Products Industry foliglurax (PXT002331)
  Industry 2 small-molecule drug
Person Person Conquet, Francois (Prexton Therapeutics 201207– CEO + founder)
     
Region Region Oss
  Country Netherlands
  City n. a. Oss
    Address record changed: 2018-03-18
     
Basic data Employees n. a.
     
    * Document for �About Section�: H. Lundbeck A/S. (3/16/18). "Press Release: Lundbeck to Acquire Prexton Therapeutics Adding Foliglurax in Clinical Phase II to Its Pipeline of Innovative Treatments for Patients Suffering from Parkinson's Disease". Valby & Oss.
     
   
Record changed: 2020-04-01

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Lundbeck (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81




» top